Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study.

Journal: Clinical, cosmetic and investigational dermatology
Published Date: Dec 18, 2024

Abstract

BACKGROUND: Vitiligo is a chronic autoimmune disease manifested by depigmented patches of skin devoid of melanocytes. Baricitinib, a JAK inhibitor selectively targeting JAK1/2, has shown preliminary efficacy for vitiligo. We aimed to assess the efficacy and tolerability of combination therapy with baricitinib and narrowband UV-B (NB-UVB) to treat active nonsegmental vitiligo (NSV).

Authors

  • Bin Zhou
    Department of Oral and Maxillofacial Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Jiachen Gui
    Department of Dermatology, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Tao Wang
    Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Zhimin Li
    Department of Dermatology, Air Force Medical Center, PLA, Beijing, People's Republic of China.
  • Wenzhi Hu
    Department of Burn and Plastic Surgery, the Air Force Medical Center of Air, Force Military Medical University of Chinese PLA, Beijing, People's Republic of China.
  • Yue Zhang
    Department of Ophthalmology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Qiang Li
    Department of Dermatology, Air Force Medical Center, PLA, Beijing, People's Republic of China.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals